IDH mutations have been associated with several cancers, in particular, WHO grade II/III and secondary glioblastoma multiforme (GBM), acute myeloid leukemia (AML), intrahepatic cholangiocarcinoma, gastric cancer and cartilaginous tumors [9,82,83,84,85]. This evidence concerns the gene IDH1 and glioblastoma.